Human Ephrin-A4/EFNA4 Protein

Cat. No. EPA-HM204

ϗͶϲϿͺͶϩ

Description	
Source	Recombinant Human Ephrin-A4/EFNA4 Protein is expressed from HEK293 with hFc tag at the C-Terminus.
	It contains Leu26-Gly171.
Accession	P52798-1
Molecular Weight	The protein has a predicted MW of 43.1 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC
Formulation and Storage	
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background	
	Ephrin A4 is one of the ephrin ligand molecules belonging to the tyrosine kinases receptor family. It was originally identified in a T-lymphoma cell line and seen to be expressed in human adult tissue as well as several tumor types. The cytoplasmic pattern of ephrin A4 could identify a subgroup of primary osteosarcoma patients with a high liability for progression, poor prognosis, and inferior response to chemotherapy.
Assay Data	

Bis-Tris PAGE



Human Ephrin-A4 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human Ephrin-A4 is greater than 95% as determined by SEC-HPLC.

Human Ephrin-A4/EFNA4 Protein

Cat. No. EPA-HM204

Assay Data

ELISA Data

Human Ephrin-A4, hFc Tag ELISA 0.2µg Human EphA7, His Tag Per Well



Immobilized Human EphA7, His Tag at 2μ g/ml (100 μ I/Well) on the plate. Dose response curve for Human Ephrin-A4, hFc Tag with the EC50 of 2.9ng/ml determined by ELISA (QC Test).

ᠺ᠕ᡗ᠋ᠴ᠊᠐᠍᠋᠋